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Introduction
A role for inﬂ ammation in the pathogenesis of Alzheimer’s 
disease (AD) had been discussed even in the earliest days 
of AD research. A hundred years ago Oskar Fischer wrote 
that cerebral senile plaque formation could be considered 
as the result of an extracellular deposition of abnormal 
substance in the cortex that induces a local inﬂ ammatory 
reaction, followed by an aberrant regenerative response 
of the surrounding nerve ﬁ bers. However, he was un-
successful in his attempts to show the morphological 
characteristics of an inﬂ ammatory response around 
plaques and to detect complement proteins by perform-
ing complement-binding studies. Seventy years later, with 
the advent of monoclonal antibodies for immuno histo-
chemistry, complement factors and clustering of 
activated microglia could be demonstrated within 
plaques [1]. After the discovery of amyloid-β (Aβ) as the 
main constituent of senile plaques, the concept was 
formed that the Aβ peptide itself can induce a local 
inﬂ ammatory response, which was supported by in vitro
ﬁ ndings showing that ﬁ brillar Aβ can bind complement 
factor C1 and activate the classical complement pathway 
without involvement of antibodies [2]. Th e inﬂ ammatory 
process in AD brains is not restricted to just a single step 
of the pathological process; inﬂ ammation-related proteins 
are involved in several crucial pathogenic events of the 
underlying pathological cascade, such as Aβ generation 
and clearance, gliosis and increased phosphorylation of 
tau with accelerated tangle formation [3,4]. It is impor-
tant to keep in mind that inﬂ ammation itself has both 
beneﬁ cial eﬀ ects, such as the phagocytosis of the toxic 
Aβ ﬁ brils, and detrimental eﬀ ects on neighboring cells by 
prolonged elevation of pro-inﬂ ammatory mediators. 
Clinicopathological studies show that the presence of 
activated microglia and inﬂ ammation-related mediators 
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in the cerebral neocortex of patients with a low Braak 
stage for AD pathology precedes extensive tau-related 
neuroﬁ brillary pathology [5] (Figure 1). Clinical research 
using positron emission tomography with the peripheral 
benzodiazepine receptor ligand PK-11195 as a marker for 
activated microglia indicates that activation of microglia 
precedes cerebral atrophy in AD patients [6]. A positron 
emission tomography study using the Pittsburg com-
pound B for visualization of ﬁ brillar amyloid and the PK-
11195 ligand for microglia activation showed that 
amyloid deposition with microglia activation can be 
detected in vivo in around 50% of patients with mild 
cognitive impairment [7]. Th us, neuropathological and 
neuroradiological studies indicate that inﬂ ammatory 
changes in AD brains are a relatively early pathogenic 
event that precedes the process of neuropil destruction. 
Th e primary focus of the present paper is to review 
human studies for genetic, epidemiological and clinical 
evidence for whether, when and how inﬂ ammation could 
increase the risk of developing AD.
Genetic evidence
In this section we evaluate the relationship between 
genetic risk factors for AD and two major components of 
amyloid plaques in AD brains, namely the presence of 
complement proteins and clusters of activated microglia, 
which are a source for the production of pro-inﬂ am-
matory cytokines.
Aβ-associated proteins
Complement proteins were the ﬁ rst molecules detected 
in senile plaques in AD brains [8], two years before the 
identiﬁ cation of Aβ as the core protein of the senile 
plaques in 1984. In the following years a growing list of 
other proteins, mostly acute phase proteins, were 
demon strated to be associated with Aβ deposits. Th ese 
so-called Aβ-associated proteins include, next to the 
complement proteins, α1-antichymotrypsin (ACT), 
apolipoprotein E (ApoE), clusterin, intercellular adhesion 
molecule-1, α2-macroglobulin, serum amyloid P 
component (SAP) and heparan sulfate proteoglycans [9-
15]. Th ese proteins play a role in the transport, 
ﬁ brillogenesis and deposition of Aβ and they are also 
important for the sequestration of neurotoxic Aβ species 
in plaques [16]. Th e presence of certain Aβ-associated 
proteins within plaques depends on the plaque type (see 
below) [17,18], and the accu mu lation of most depends on 
a certain degree of Aβ ﬁ brillization; for example, SAP is 
found especially in plaques with ﬁ brillar Aβ deposits but 
not in diﬀ use plaques [18]. In vitro studies also indicate 
that a certain degree of ﬁ bril formation is necessary for 
SAP to bind to Aβ, as SAP was found to bind to mature 
ﬁ brils but not to protoﬁ brils of Aβ1-42 [19].
Neuropathological studies show that diﬀ use Aβ deposits, 
characterized by the presence of non-ﬁ brillar (non-
congophilic) Aβ and without neuritic changes or reactive 
glia, are the predominant plaque types in non-demented 
controls, and that the amount of ﬁ brillar (congophilic) 
Aβ deposits increases with progression of the disease 
[20]. In contrast to the classic plaques, characterized by 
highly ﬁ brillar Aβ deposits, the list of Aβ-associated 
proteins present in diﬀ use plaques is much shorter. 
Immunohistochemical studies have demonstrated that 
ApoE, clusterin, complement proteins and ACT are 
present in diﬀ use plaques [17]. Studies in transgenic mice 
expressing the causal AD mutations crossed with 
transgenic mice overexpressing or genetically depleted 
for amyloid-associated proteins such as complement 
factors, ApoE, clusterin and ACT have shown that these 
proteins have an important role in the dynamic balance 
Figure 1. Pathological cascade in Alzheimer’s disease brains. The occurrence of amyloid-β deposits, glial response and tau-neurofi brillary 
pathology in the mid-temporal cortex compared to the neuropathological staging of Alzheimer’s disease (modifi ed after [5]).
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between Aβ deposition and removal [21-25]. Four recent 
large genome-wide association studies in late-onset AD 
have documented, in addition to the ApoE ε4 allele 
genotype, nine novel loci as risk factors for developing 
AD, includ ing genes encoding proteins implicated in 
inﬂ ammatory processes (clusterin (CLU, chromosome 8, 
rs11136000) and complement receptor-1 (CR1, chromo-
some 1, rs6656401)) [26,27]. Clusterin is a multifunctional 
protein involved in both complement attack inhibition 
and cholesterol metabolism, and complement receptor-1 
is the receptor for the cleavage products of complement 
proteins 3 and 4, which are present in plaques. All nine 
new genes map onto three pathways leading to late-onset 
AD: immune system function, cholesterol metabolism, 
and synaptic dysfunction [28]. Diﬀ use plaques, the initial 
pathological lesion in AD, contain a limited number of 
proteins, which are now all linked with a genetic risk for 
AD, with ACT as the exception. Abnormalities in the 
generation of Aβ are considered as the causal factor for 
the familial forms of early-onset AD, whereas poly-
morphisms of the genes encoding for ApoE, clusterin and 
complement proteins are the genetic risk factors for late-
onset AD. Genome-wide association studies for late-
onset AD have not revealed genetic factors related to Aβ 
generation but instead to the Aβ-associated proteins 
already present in the initial neuropathological lesion. 
Taken together, the data on the protein composition of 
diﬀ use plaques and the recent genetic ﬁ ndings strongly 
suggest an interaction between Aβ, cholesterol metabo-
lism and complement activation in the initial steps of the 
pathological cascade in AD.
Glia and pro-infl ammatory cytokines
Fibrillar Aβ plaques are associated with clustering of 
activated microglia and astrocytes. Th ese glial cells play 
an important role in innate immunity and express a 
family of receptors, the Toll-like receptors (TLRs), as a 
ﬁ rst line of defense responsible for recognizing speciﬁ c 
pathogen-associated molecular patterns like ﬁ brillar Aβ. 
TLRs and CD14, both innate immunity receptors, 
mediate activation of transcription factors such as NF-κB 
and subsequently the production of inﬂ ammatory cyto-
kines [29]. Accumulating evidence indicates that CD14 
and TLR4 are essential in the interaction of glial cells 
with Aβ for the production of pro-inﬂ ammatory cyto-
kines [30-32]. In vitro studies have shown that Aβ ﬁ brils 
interact with the TLR2/4 accessory protein CD14 and 
both TLR2 and TLR4 mediate Aβ-induced production of 
TNF-α in human monocytes. Mouse microglia show in 
vitro increased ingestion of Aβ after activation of TLR2, 
TLR4 or TLR9. Stimulation of the innate immune system 
via TLR9 is reported to be highly eﬀ ective at reducing the 
parenchymal and vascular amyloid burden without 
apparent toxicity in a transgenic AD mouse model [33]. 
Both Aβ and the oxidized low-density lipoprotein can 
trigger inﬂ ammatory signaling through a TLR4 and -6 
heterodimer. Th is assemblage is regulated by signals from 
the scavenger receptor CD36 [34]. Th ese data show that 
CD36-TLR4-TLR6 activation is a common molecular 
mechanism by which atherogenic lipids and Aβ stimulate 
an inﬂ ammatory response in arteriosclerosis and AD, 
respectively. Arteriosclerosis is a major risk factor for 
late-onset AD and the discussed ﬁ ndings suggest that 
both dis orders share a common pathogenic mechanism 
rooted in the innate immune system. Introducing a 
functionally destructive mutant of TLR4 into a transgenic 
mouse model (APPswe/PS1) results in increased levels of 
Aβ deposits, as well as reduced microglia activity [35]. 
Microglia from CD14 null mice failed to aﬀ ect Aβl-42 
damaged neurons and neuronal survival was accom-
panied by a signiﬁ cant reduction in the production of 
IL-6, indicative of reduced microglial activation [36]. All 
these data suggest that activation of TLR4 and CD14 
signaling is involved in both the detrimental production 
of pro-inﬂ ammatory cytokines as well as the beneﬁ cial 
removal of Aβ in AD, illustrating the two-edged sword 
aspect of the neuroinﬂ ammatory response in AD brains 
[37]. Experimental animal studies indicate that microglia 
‘acivation’ is not simply one phenotypic manifestation but 
includes heterogeneous, functional phenotypes that 
range from a pro-inﬂ ammatory, classic activation state to 
an alternative activation state involved in repair and 
extracellular matrix remodeling [38,39].
Lipopolysaccharide (LPS), a bacterial coat component, 
is widely used as a potent stimulator of the innate 
immune system and it is recognized by a receptor 
complex containing fully functional TLR4 and CD14. 
Chronic neuroinﬂ ammation induced by LPS in rats 
reproduced components of the neurobiology of AD, such 
as increased activation of microglia and astrogliosis, 
increased tissue levels of IL-1 and TNF-α, elevated 
expression of the amyloid precursor protein, and a work-
ing memory deﬁ cit [40]. Innate immunity responsive ness 
can be investigated by the incubation of whole blood 
samples with LPS, followed by the determination of levels 
of various inﬂ ammatory cytokines. Twin studies demon-
strate that heritability for serum levels of circulating 
inﬂ ammatory mediators is modest (about 20%). In con-
trast to circulating inﬂ ammatory mediators, however, 
cytokine production capacity is under strong genetic 
control. In the non-diseased population, estimates for the 
heritability of the production of the various cytokines 
ranges from 53 to 86% [41]. We have studied cytokine 
production capacity in ex vivo stimulated full blood 
samples from middle aged oﬀ spring with and without a 
parental history of late-onset AD [42]. We found that the 
production capacity of the pro-inﬂ ammatory cytokines 
IL-1β, IL-6, TNFα and interferon-γ was signiﬁ cantly 
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higher in oﬀ spring with a parental history of AD upon 
stimulation of whole blood with LPS. Similar results were 
found for the IL-1β to IL-1 receptor antagonist (IL-1ra) 
ratio, which was calculated because IL-1ra is the natural 
antagonist of the pro-inﬂ ammatory cytokine IL-1β. Th is 
higher ratio reﬂ ects a pro-inﬂ ammatory genotype. While 
the ApoE ε4 allele genotype was more frequent among 
the oﬀ spring with compared to those without a parental 
history of AD, these ﬁ ndings were independent of ApoE4 
genotype. In contrast to the stimulated whole blood 
samples, the evaluation of the unstimulated blood samples 
does not show signiﬁ cant diﬀ erences between the 
oﬀ spring with versus without a parental history of late-
onset AD. Th e aim of this study was not to identify the 
genetic variability of a particular receptor or cytokine but 
to investigate the genetic contribution of the whole 
pathway that mediates the production of pro-inﬂ am-
matory cytokines after activation by LPS of the innate 
immune receptors CD14 and TLRs by LPS. Similar to 
LPS, the Aβ-induced cytokine production capacity is also 
under genetic control, as shown by results from twin 
studies in which whole blood samples were ex vivo 
stimulated with Aβ [43].
In conclusion, neuropathological and experimental 
studies indicate that ﬁ brillar Aβ can activate the innate 
immunity-related CD14 and TLR signaling pathways for 
pro-inﬂ ammatory cytokine production. Th e production 
capacity of this pathway is under genetic control and 
oﬀ spring with a parental history of late-onset AD have a 
higher production capacity for pro-inﬂ ammatory cytokines.
Epidemiological evidence
Prospective case cohort studies have shown that high 
serum levels of the acute-phase proteins ACT, C-reactive 
protein and IL-6 could predict cognitive decline or 
dementia [44-46]. Yaﬀ e and colleagues [47] reported that 
elderly subjects with a metabolic syndrome and high 
serum level of IL-6 and C-reactive protein were more 
likely to experience cognitive decline in the next four 
years, compared with those with a metabolic syndrome 
and low levels of these inﬂ ammatory proteins. In another 
population study the metabolic syndrome was also 
negatively associated with cognition, especially in 
subjects with high levels of inﬂ ammation [48]. In the 
Framingham study a higher spontaneous production of 
IL-1β or TNF-α by peripheral blood mononuclear cells 
was associated with future risk of AD in older individuals 
[49]. Th e epidemiological ﬁ ndings from several case 
cohort studies indicate that non-demented subjects with 
increased serum levels of acute-phase reactants, indicat-
ing a low-grade peripheral systemic inﬂ ammation, are at 
risk for developing a sporadic late-onset form of AD.
Th e acute phase response is initiated and orchestrated 
by cytokines, most notably IL-1. AD brains are 
charac ter ized by overexpression of IL-l and there are 
strong arguments for an important role for IL-1 in 
amyloid plaque formation [50]. Aβ deposition and 
neuronal injury may trigger a self-propagating cytokine 
cycle, which initiates a vicious feedback of continuing IL-
1 elevation when chronically induced. In this way further 
neuronal dysfunction and Aβ plaque accumulation could 
be promoted. Taken together, the epidemiological studies 
suggest that elevated serum levels of acute phase 
reactants can be considered as a risk factor for AD and 
neuropathological data demonstrate the presence of 
acute phase reactants already in human brains with 
preclinical stages of AD pathology (low Braak score). 
Studies suggesting that immune blood markers can be 
used as a clinical test to identify those patients with mild 
cognitive impairment who progress to clinical AD are 
consistent with the view that peripheral immune and 
inﬂ ammatory mechanisms contribute to the pathogenesis 
of AD [51,52].
Clinical evidence
Th e question of whether systemic inﬂ ammation or 
peripheral chronic inﬂ ammation could contribute to AD 
pathology was a neglected research topic until recently. 
In particular, the dogmatic belief that the blood-brain 
barrier excludes cross-talk between both systems 
hampered studies in this ﬁ eld for a long time. Th is view 
has changed dramatically, however, as it became clear 
that morphological ‘delegates’ of the immune system, the 
microglial cells, are present in the brain and that the 
peripheral lymphoid organs are innervated. A further 
ﬁ nding was that cytokines and neurotransmitters, as well 
as their receptors, are endogenous to both the brain and 
the immune system. Th ese ﬁ ndings have led to the view 
that the immune system and brain share a common 
biochemical language and that their functions are 
intertwined [53]. Pro-inﬂ ammatory cytokines such as 
IL-1β and TNF-α, which are generated in the periphery, 
communicate with the brain. Several mechanisms exist 
by which an initial, exclusively peripheral cytokine signal 
can be transmitted to the brain, including direct neural 
pathways (via primary autonomic aﬀ erents) that trans-
port it across the blood-brain barrier, or entry via the 
cirvumventricular region, where the blood-brain barrier 
is non-existent or discontinuous [54].
Several clinical studies suggest that systemic inﬂ am-
mation can be involved in the pathogenesis of AD. In a 
twin study it was found that AD cases with a history of 
severe systemic infection tended to have earlier onset 
than their corresponding twin [55]. A case-control case 
study reported a positive association between episodes of 
infection during the four years preceding the diagnosis 
and an increased likelihood of a diagnosis of AD in older 
individuals [56]. In a prospective cohort study of 
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community-dwelling subjects with mild to severe AD it 
was found that acute episodes of systemic inﬂ ammation 
with increased serum levels of TNF-α were associated 
with a two-fold increase in the rate of cognitive decline 
over a 6-month period. High baseline levels of TNF-α 
were associated with a four-fold increase in the rate of 
cognitive decline while subjects who had low levels of 
TNF-α throughout the study showed no cognitive decline 
over the 6-month period [57]. Recent studies indicate 
that chronic periodontitis has been associated with AD. 
Periodontitis is a prevalent, persisting peripheral infec-
tion associated with Gram-negative, anaerobic bacteria 
that are capable of exhibiting localized and systemic 
infection in the host. Emerging evidence suggests that 
tooth loss and periodontal disease predict cognitive 
decline in community-dwelling older adults [58]. In 
addition, patients with AD had higher levels of plasma 
TNF-α and antibodies against periodontal bacteria com-
pared with cognitively normal subjects [59]. Although 
several case-control and prospective studies indicate 
periodontitis as a risk factor for cognitive decline, it is 
important to be cautious to draw any conclusion about a 
causal relationship. Premorbid cognition is important 
both for oral health and a risk factor for dementia. 
Furthermore, factors other than inﬂ ammatory mediators 
could be responsible for the positive association, such as 
changes in life style and dietary factors, such as a poor 
nutritional status, especially in relationship to B vitamins.
Most interesting with regard to understanding the 
contribution of systemic inﬂ ammation to the patho gene-
sis of AD seems to be current research into the role of 
inﬂ ammation in delirium. Delirium is deﬁ ned as an acute 
disturbance of consciousness with signs of attention, a 
typically ﬂ uctuating course and a change in cognition 
(that is, disorientation, disturbed memory). Delirium is 
the most prevalent neuropsychiatric syndrome that can 
be observed in the general hospital, especially in older 
patients with preexisting cognitive impairment. It is 
independently associated with increased mortality, insti-
tutionali zation and dementia [60]. Many clinical condi-
tions that are accompanied by systemic inﬂ ammatory 
reactions can induce delirium. A case-controlled neuro-
patho logical study has shown an association between 
severe systemic infection (sepsis) and microglia activa-
tion [61]. A recent postmortem study found that delirium 
is associated with higher immunoreactivity for microglial 
and astroglial activity and IL-6 compared with age-matched 
controls without delirium [62]. In healthy persons a 
severe systemic inﬂ ammation, such as sepsis, can lead to 
delirium, but in patients with preexisting brain pathology 
even just a mild urinary tract infection can cause it [63]. 
Experimental animal studies have shown that microglia 
respond diﬀ erently to a stimulus if other stimuli precede, 
coexist or follow it. Microglia can become primed by an 
initial factor, which prepares them for an enhanced pro-
inﬂ ammatory cytokine response, even if the subsequent 
challenges are only mild [64]. Signiﬁ cantly increased 
serum levels of IL-6 were found in acutely admitted older 
patients with delirium compared to those without 
delirium after adjusting for infection, age and cognitive 
decline [65]. Th is study indicates that acute phase reac-
tants could contribute to the pathogenesis of delirium. A 
high incidence of delirium is seen in older patients 
undergoing surgery for hip fracture. Contrary to popular 
belief, there is little evidence that general anesthesia is 
associated with delirium after surgery [66]. Th e most 
important predisposing factor for delirium in these 
patients is preexisting cognitive decline or dementia. Th e 
precipitating factors could be related to the release of 
pro-inﬂ ammatory cytokines as a consequence of the 
fracture and tissue destruction resulting from surgery. In 
a time course study of cytokines during delirium in older 
patients admitted for surgery after hip fracture, signiﬁ -
cant diﬀ erences in serum levels of IL-6 were found 
between patients with and without delirium [67].
For a long time it has been a common observation in 
medicine that, when older patients become delirious 
while suﬀ ering from an acute urinary tract or other 
common infection, treatment of the infection may go 
well but the patients emerge with dementia, even when 
they had appeared cognitively intact or only mildly 
impaired prior to hospitalization. Th ese patients often 
fail to recover to their initial level of functioning and 
some never resume independent life at home. Similar 
clinical observations have been made after postoperative 
delirium in elderly hip fracture patients free from 
preexisting dementia [68-70]. Th ere is now increasing 
evidence that postoperative delirium after hip surgery is 
an important predictor of incident dementia in elderly 
patients living independently at home [70]. In a pros-
pective study it was found that, after a follow-up of 
2.5 years, the risk of dementia or mild cognitive impair-
ment is almost doubled in elderly hip surgery patients 
with postoperative delirium compared with at-risk patients 
without delirium [68]. It has recently been reported that 
delirious episodes in a cohort of AD patients accelerate 
cognitive decline [71].
In conclusion, recent studies suggest that delirium and 
AD share a neuroinﬂ ammatory response as a common 
pathogenic mechanism that could explain the vulnera-
bility of AD patients for further cognitive worsening after 
an episode of delirium associated with a systemic 
inﬂ ammatory reaction.
Discussion
Th e etiology of AD may be heterogeneous, but the 
underlying pathological cascade has distinct common 
themes. In the autosomal dominant form of familial AD 
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the etiology is related to causal mutations leading to 
higher production of Aβ1-42. Th e subsequent deposition 
of ﬁ brillar Aβ elicits a brain inﬂ ammatory response as a 
secondary event in the pathological process. In contrast 
to the monocausal etiology of this rare form of AD, the 
etiology of the highly prevalent sporadic late-onset form 
is considered to be multifactorial. Genome-wide asso-
ciation studies of late-onset AD strongly suggest a role 
for lipoproteins and immune-associated proteins in its 
etiology and pathogenesis. In addition to the role of ApoE 
and clusterin in the process of Aβ deposition and 
drainage, these proteins can also attenuate the activity of 
NF-κB signaling and the production of pro-inﬂ ammatory 
cytokines [72,73]. Th e ﬁ brillar Aβ-induced inﬂ ammatory 
response is a relatively early event in the pathological 
cascade and it is already present in the brain during 
stages of the disease that precede the stages characterized 
by tau-related neuroﬁ brillary changes, which are most 
closely related to a clinical dementia syndrome (Figure 1).
Animal and neuropathological studies in humans show 
that systemic inﬂ ammation can induce an inﬂ ammatory 
response within the brain. Th is response can lead to acute 
cognitive disturbance and behavior changes (delirium) 
[74]. In healthy adults only a severe systemic inﬂ am ma-
tion can induce delirium, but in older people, especially 
those with mild cognitive impairment or dementia, even 
just a mild systemic inﬂ ammation can lead to it [75]. 
Inﬂ ammation-induced delirious episodes in adults with 
preexisting normal cognitive functions are frequently 
followed by a period of cognitive impairment that can 
last for months, although there is no evidence in these 
cases for a further progression of the cognitive symptoms 
to a clinical AD syndrome. However, inﬂ ammation-
induced delirium in older patients with preexisting mild 
Figure 2. Relationship between infl ammation and the etiology and clinical syndrome of Alzheimer’s disease. Schematic diagram showing 
that interactions between innate immunity-related genetic risk factors and infl ammation-inducing events (brain trauma, ischemia and infection) 
can contribute to the multifactorial etiology of the sporadic late-onset form of AD. The diagram illustrates also that delirium and AD share a 
neuroinfl ammatory response as a common pathogenic mechanism that could explain the vulnerability of AD patients to further cognitive 
worsening after an episode of delirium associated with a systemic infl ammatory response. Aβ, amyloid-β peptide; AD, Alzheimer’s disease; APOE4, 
apolipoprotein E4; APP, amyloid precursor protein; CLU, clusterin; CR1, complement receptor-1; PS1, presenilin-1; PS2, presenilin-2.
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cognitive impairment can lead to further cognitive 
deterioration and dementia (Figure  2). Th ese clinical 
ﬁ nd ings suggest that systemic inﬂ ammation does not 
initiate the pathological AD cascade but can accelerate 
the underlying cascade.
What makes older patients with peripheral inﬂ am-
mation so vulnerable to dementia? Several mechanisms 
can play a role. First, neuropathological studies show 
inﬂ ammatory changes in early stages of AD pathology, 
such as ﬁ brillar Aβ-induced microglia activation. Micro-
glia cells are already ‘primed’ in preclinical stages of AD 
for increased production of pro-inﬂ ammatory cytokines 
later on by systemic inﬂ ammation as a second challenge. 
Second, neurotransmitters such as acetylcholine play an 
active role in controlling glia activation and can inhibit 
the production of proinﬂ ammatory cytokines [76]. AD 
brains are characterized by cholinergic deﬁ cits that can 
contribute to an uncontrolled neuroinﬂ ammatory 
response when the brain is challenged by peripheral 
inﬂ ammation. Th ird, arteriosclerosis and other vascular 
risk factors common in older people lead to blood-brain 
barrier dysfunction with brain endothelial cell activation 
resulting in the secretion of multiple neurotoxic and 
inﬂ ammatory factors. Th ese factors could be responsible 
for the increased susceptibility of the brain to systemic 
inﬂ ammatory mediators [77,78]. Th is could also explain 
why the prevalence of delirium in demented patients in 
late-onset AD and vascular dementia is higher than in 
those with early onset AD [79].
Th e pathological, epidemiological and clinical ﬁ ndings 
reviewed in this paper suggest that several inﬂ ammation-
related events can contribute to the pathogenesis of AD 
and accelerate the rate of progression of the clinical 
course of AD. However, this view does not necessarily 
indicate that treatment with anti-inﬂ ammatory drugs will 
be eﬀ ective in AD patients. As discussed earlier, inﬂ am-
mation itself has both beneﬁ cial and detrimental eﬀ ects 
and every inﬂ ammation-based therapeutic strategy inﬂ u-
ences the delicate balance between both eﬀ ects. Inhibi-
tion of complement activation or blocking of IL-1β have 
been considered as therapeutic options for treatment of 
AD patients. However, it appeared that complement C3 
deﬁ ciency in transgenic AD mice led to accelerated 
amyloid plaque formation and overexpression of IL-1β to 
a reduction of amyloid pathology [21,22,80]. Th ese ﬁ nd-
ings indicate potential negative eﬀ ects of anti-inﬂ amma-
tory drugs in AD patients if these drugs inhibit the 
primary function of the innate immune system: removal 
of the pathological agents (ﬁ brillar Aβ) that induce the 
inﬂ ammatory response. Epidemiological and observa-
tional studies in humans have found evidence that the 
use of non-steroidal anti-inﬂ ammatory drugs (NSAIDs) 
is associated with a lower risk of developing AD. In 
contrast, randomized trials have reported no eﬀ ect of 
NSAIDs on clinical progression in patients with clinically 
established AD [81]. An explanation for these apparently 
divergent conclusions could be the fact that expression 
levels of cyclooxygenase-1 and -2, as the main targets of 
NSAIDs, are dependent on the stage of AD pathology [82].
Further directions
Th e view that peripheral inﬂ ammation can increase the 
risk of dementia in older people oﬀ ers scope for 
prevention. In particular, clinical trials are warranted to 
investigate whether anti-inﬂ ammatory drugs can prevent 
further cognitive decline in patients with mild cognitive 
impairment during the periods that peripheral inﬂ am-
mation exerts increased inﬂ ammatory pressure on the 
brain. Th ese studies could be performed using available 
drugs that inhibit microglia activation, such as mino-
cycline, or that restore the cholinergic control of micro-
glia activation by cholinomimetics [63]. Minocy cline, a 
tetracycline derivative with anti-inﬂ ammatory properties, 
attenuates the production of pro-inﬂ amma tory cytokines 
by human microglia without aﬀ ecting their beneﬁ cial 
activities, such as phagocytosis of Aβ ﬁ brils [83].
Conclusion
Genetic, pathological and epidemiological studies show 
that innate immunity is involved in the early stages of the 
pathological cascade of AD and can also contribute to the 
etiology of late-onset AD. Clinical studies suggest that 
peripheral inﬂ ammation increases the risk of dementia, 
especially in patients with preexisting cognitive 
impairment, and accelerates further deterioration in 
demented patients.
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